Ajay Gautam, Executive Director & Head, AsiaPac & Emerging Markets BD at AstraZeneca.png

Book release – Drugs, Politics & Innovation: An Emerging Markets Cocktail

Our former BioPharma Mexico speaker Ajay Gautam, Executive Director & Head, AsiaPac & Emerging Markets BD at AstraZeneca has just announced the release of his new book. The book is available in Kindle, Paperback and Hardcover on Amazon > “In this book, I have discussed my journey through several emerging markets in the context of healthcare innovation using case studies of start-up …

Ajay Gautam of AstraZeneca spoke at BioPharma Mexico 2014

AstraZeneca’s Ajay Gautam on innovation in emerging markets

Last year’s BioPharma Mexico was a huge success, and we were excited to have Ajay Gautam, Executive Director and Head of Emerging Markets for AstraZeneca, as one of our speakers. Ajay has a broad experience in Big Pharma, start-ups, private equity, and venture capital with the last 7 years spent in the Emerging Markets of Latin America, Middle East, and Northern Africa. In …

BioPharma Mexico - Emerging markets

Innovation in emerging markets

In the latest of his series of articles on emerging markets innovation (Nature Reviews Drug Discovery, Sept 2014; Nature Reviews Drug Discovery, Jan 2015; JMDS, June 2015; Drug Discovery Today, July 2015), Dr. Ajay Gautam has published a new study in the August issue of Nature Review Drug Discovery to review these markets at a granular, therapeutic area level. The …

Emerging Markets

Strategies for bioclusters in emerging markets

In a new study published in Nature Reviews Drug Discovery, Dr. Ajay Gautam at AstraZeneca has proposed a framework for innovation bioclusters across the emerging markets. By analyzing 8 Chinese bioclusters according to their academic and entrepreneurial activity, Dr. Gautam has classified bioclusters as emerging Innovation Leaders, Untapped Talent, Niche Hubs and Aspiring clusters. He has further proposed investment policies …

Attitudes on global clinical trials

Download eBook: Key factors surrounding the growth in global clinical trials

Clinicaltrials.gov indicates that more than half of clinical trials are being conducted outside the United States in developing countries, and that number is expected to grow. Why the dramatic change in acceptance of global clinical trials? Lionbridge Life Sciences had an opportunity to hear directly from many respected members of the Drug Information Association (DIA) at their 2014 Annual Meeting …

Download: Considerations in building a pipeline of mAb biosimilars for emerging markets

Download this presentation here > The World Biosimilar Congress  brings together pharma, biotech, academia and regulators and the wider service provider community to discuss the latest R&D, process, production, regulation and to-market strategies for biosimilar medicines. At the 2013 event, delegates were fortunate enough to hear from Dr Roman Ivanov, Vice President, R&D, BIOCAD, who delivered the presentation ‘Considerations in building a pipeline of mAb biosimilars for Asian, …

Why big pharma invests in some emerging markets and not in others

This was presented by AstraZeneca’s Executive Director & Head of External Collaborations for Emerging Markets, Ajay Gautam, at the Biopharma Mexico Convention held in Mexico City last October. AZ, along with other big pharma, have looked to emerging markets such as Brazil, China, Korea, Taiwan, Russia and Israel for innovation. What do these markets have that make them attractive for investment? …

Whitepaper: Regulatory and Ethical Compliance in Emerging Markets

The China-based divisions of international firms are increasingly finding themselves in the view of government investigations. The current bribery allegations concerning a leading pharmaceutical brand highlight the need to account for regulatory and cultural gaps between Western and emerging economies. Download whitepaper here > The fastest-growing drug market, China is expected to be worth US$ 370 billion by 2020. As …

Discounts needed to access China pharma market

"If we can arrange an appropriate, acceptable, affordable price, then you can have a huge market," says China's top health official, Chen Zhu, who stepped down last month (Bloomberg). Health-care spending in China – now the world' third-largest pharmaceutical market – is expected to almost triple by 2020 to $1 trillion a year. However, if Western pharmaceutical companies want to …

Sanofi plans China growth with 4 new plants

Sanofi plans to open four manufacturing plants this year in China, reports the Wall Street Journal. The WSJ reports that Sanofi expects to see "double-digit sales growth" in the next five years in China, and plans to expand its animal health and vaccine business in the country. The French pharmaceutical company currently has six plants in China, but the addition …